Biotech
Seaport Therapeutics
Seaport Therapeutics raises $225M Series C at $1.2B valuation
$225M
Total Raised
Series C
Latest Round
2020
Founded
100+
Employees
Boston, MA
1 min read
Quick Facts
Valuation
$1.2B
Latest Round Size
$225M
Latest Round Date
September 2024
Seaport Therapeutics: Series C Funding Round
Seaport Therapeutics has successfully raised $225M in Series C funding, reaching a valuation of $1.2B.
Company Overview
Neuropsychiatric disease treatments
Funding Details
The Series C round was led by Fidelity, with participation from T. Rowe Price.
Company Information
- Headquarters: Boston, MA
- Founded: 2020
- Employees: 100+
- Category: Biotech
Investment
Seaport Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
Key Investors
Fidelity
Lead Investor
Verified investor in Series C
T. Rowe Price
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M